NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)

The summary for the NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional): NEPS Concept # 1862 This concept seeks to support exploratory basic research on interpersonal racism and on parsing the complex effects of structural racism into sub-components and their impact on neurocognition, with an emphasis on informing preventive interventions.

Federal Grant Title:	NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-23-029
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 14th, 2024
Original Application Deadline:	November 14th, 2024
Posted Date:	August 9th, 2022
Creation Date:	August 9th, 2022
Archive Date:	December 20th, 2024
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 9th, 2022

Applicants Eligible for this Grant: Public and State controlled institutions of higher education - Private institutions of higher education - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-029.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Option...; • Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/...; • Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clini...; • Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Betwee...; • Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Betwee...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...; • Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not All...; • U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 C...; • Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Option...; • Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional)